Stocks
Incyte Corporation

Incyte CorporationINCY

NASDAQHealthcareBiotechnology$121.47+0.55%

Price as of · delayed, not real-time

A biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, primarily in oncology. Investors track Incyte for its flagship product Jakafi (ruxolitinib) and pipeline of novel cancer treatments targeting JAK and other pathways.

Market Cap: $18.4B52W Range: $81.09-$132.60

Congressional Interest in Incyte Corporation (INCY)

9 members of Congress have disclosed 26 trades in Incyte Corporation (INCY), a Healthcare company. The buy/sell breakdown shows 14 purchases versus 12 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.

Total Disclosures
26
Unique Politicians
9
Buys
14
Sells
12

Who in Congress Is Trading INCY?

2026-05-15$1K-$15K
Stock
2026-03-30$1K-$15K
Stock
2026-03-10$1K-$15K
Stock
2026-01-29$1K-$15K
Stock
2025-05-15$1K-$15K
Stock
2025-02-19$1K-$15K
Stock
2024-12-18$1K-$15K
Stock
2024-11-15$1K-$15K
Stock
2024-08-05$1K-$15K
Stock
2024-08-02$1K-$15K
Stock
2024-04-23$50K-$100K
Stock
2023-10-26$1K-$15K
Stock
2023-03-06$1K-$15K
Stock
2021-09-05$1K-$15K
Stock
2020-12-22$1K-$15K
Stock
2020-11-13$50K-$100K
Stock
2020-09-16$1K-$15K
Stock
2018-11-12$1K-$15K
Stock
2017-09-08$1K-$15K
Stock
2016-11-01$50K-$100K
Stock
2016-09-27$1K-$15K
Stock
2012-06-02$15K-$50K
Stock
2011-12-01$15K-$50K
Stock
2011-02-06$2,937.98
Stock
2001-10-12$1K-$15K
Stock
2001-10-12$1K-$15K
Stock